2 days Ago By ABMN Staff
NeoGenomics, Inc. ( NASDAQ:NEO – Get Free Report ) has earned a consensus rating of “Buy” from the nine ratings firms that are currently covering the company, Marketbeat.com reports.
Nine analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have covered the stock in the last year is $20.25.
Several research analysts have weighed in on the company. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price objective on shares of NeoGenomics in a research report on Wednesday.
Benchmark restated a “buy” rating and set a $18.00 price target on shares of NeoGenomics in a research report on Tuesday, September 24th. Finally, Stephens reaffirmed an “overweight” rating and issued a $19.
00 price objective on shares of NeoGenomics in a research report on Tuesday, July 30th. Check Out Our Latest Analysis on NEO Institutional Inflows and Outflows NeoGenomics Price Performance NEO opened at $15.77 on Tuesday.
NeoGenomics has a 1 year low of $12.77 and a 1 year high of $21.22.
The company has a debt-to-equity ratio of 0.37, a current ratio of 1.99 and a quick ratio of 1.
93. The company has a market capitalization of $2.02 billion, a price-to-earnings ratio of -25.
85 and a beta of 1.19. The firm’s fifty day moving average price is $14.
68 and its two-hundred day moving average price is $14.75. NeoGenomics ( NASDAQ:NEO – Get Free Report ) last released its quarterly earnings results on Tuesday, November 5th.
The medical research company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.
04. The business had revenue of $167.80 million for the quarter, compared to analysts’ expectations of $167.
00 million. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.
11%. The firm’s revenue for the quarter was up 10.5% compared to the same quarter last year.
During the same period in the previous year, the company earned ($0.06) earnings per share. As a group, analysts anticipate that NeoGenomics will post -0.
21 earnings per share for the current fiscal year. NeoGenomics Company Profile ( Get Free Report NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments.
The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. See Also Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter .
.
